216 related articles for article (PubMed ID: 29946852)
1. [Neuroendocrine prostate cancer].
Tritschler S; Erdelkamp R; Stief C; Hentrich M
Pathologe; 2018 Jul; 39(4):333-343. PubMed ID: 29946852
[TBL] [Abstract][Full Text] [Related]
2. [Neuroendocrine prostate cancer].
Tritschler S; Erdelkamp R; Stief C; Hentrich M
Urologe A; 2017 Nov; 56(11):1475-1484. PubMed ID: 29063171
[TBL] [Abstract][Full Text] [Related]
3. Chromogranin A and neurone-specific enolase serum levels as predictors of treatment outcome in patients with metastatic castration-resistant prostate cancer undergoing abiraterone therapy.
Heck MM; Thaler MA; Schmid SC; Seitz AK; Tauber R; Kübler H; Maurer T; Thalgott M; Hatzichristodoulou G; Höppner M; Nawroth R; Luppa PB; Gschwend JE; Retz M
BJU Int; 2017 Jan; 119(1):30-37. PubMed ID: 27037533
[TBL] [Abstract][Full Text] [Related]
4. Chromogranin A: a useful biomarker in castration-resistant prostate cancer.
Ploussard G; Rozet F; Roubaud G; Stanbury T; Sargos P; Roupret M
World J Urol; 2023 Feb; 41(2):361-369. PubMed ID: 36527470
[TBL] [Abstract][Full Text] [Related]
5. Phase II study of carboplatin and etoposide in patients with anaplastic progressive metastatic castration-resistant prostate cancer (mCRPC) with or without neuroendocrine differentiation: results of the French Genito-Urinary Tumor Group (GETUG) P01 trial.
Fléchon A; Pouessel D; Ferlay C; Perol D; Beuzeboc P; Gravis G; Joly F; Oudard S; Deplanque G; Zanetta S; Fargeot P; Priou F; Droz JP; Culine S
Ann Oncol; 2011 Nov; 22(11):2476-2481. PubMed ID: 21436186
[TBL] [Abstract][Full Text] [Related]
6. Influence of abiraterone acetate on neuroendocrine differentiation in chemotherapy-naive metastatic castration-resistant prostate cancer.
Dong B; Fan L; Wang Y; Chi C; Ma X; Wang R; Cai W; Shao X; Pan J; Zhu Y; Shangguan X; Xin Z; Hu J; Xie S; Kang X; Zhou L; Xue W
Prostate; 2017 May; 77(13):1373-1380. PubMed ID: 28804908
[TBL] [Abstract][Full Text] [Related]
7. Prostate-specific antigen response to deferred combined androgen blockade therapy using bicalutamide predicts survival after subsequent oestrogen and docetaxel therapies in patients with castration-resistant prostate cancer.
Kijima T; Fujii Y; Yokoyama M; Ishioka J; Matsuoka Y; Numao N; Saito K; Koga F; Masuda H; Kawakami S; Kihara K
BJU Int; 2012 Oct; 110(8):1149-55. PubMed ID: 22369348
[TBL] [Abstract][Full Text] [Related]
8. Anticancer Activity and Tolerance of Treatments Received Beyond Progression in Men Treated Upfront with Androgen Deprivation Therapy With or Without Docetaxel for Metastatic Castration-naïve Prostate Cancer in the GETUG-AFU 15 Phase 3 Trial.
Lavaud P; Gravis G; Foulon S; Joly F; Oudard S; Priou F; Latorzeff I; Mourey L; Soulié M; Delva R; Krakowski I; Laguerre B; Théodore C; Ferrero JM; Beuzeboc P; Habibian M; Rolland F; Deplanque G; Pouessel D; Zanetta S; Berdah JF; Dauba J; Baciuchka M; Platini C; Linassier C; Tubiana-Mathieu N; Machiels JP; Kouri CE; Ravaud A; Suc E; Eymard JC; Hasbini A; Bousquet G; Culine S; Boher JM; Tergemina-Clain G; Legoupil C; Fizazi K
Eur Urol; 2018 May; 73(5):696-703. PubMed ID: 29074061
[TBL] [Abstract][Full Text] [Related]
9. Chromogranin A and neurone-specific enolase variations during the first 3 months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer.
Fan L; Wang Y; Chi C; Pan J; Xun S; Xin Z; Hu J; Zhou L; Dong B; Xue W
BJU Int; 2017 Aug; 120(2):226-232. PubMed ID: 28107595
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and cisplatin in patients with metastatic androgen independent prostate cancer and circulating neuroendocrine markers.
Culine S; El Demery M; Lamy PJ; Iborra F; Avancès C; Pinguet F
J Urol; 2007 Sep; 178(3 Pt 1):844-8; discussion 848. PubMed ID: 17631339
[TBL] [Abstract][Full Text] [Related]
11. Low PSA metastatic androgen- independent prostate cancer.
Sella A; Konichezky M; Flex D; Sulkes A; Baniel J
Eur Urol; 2000 Sep; 38(3):250-4. PubMed ID: 10940696
[TBL] [Abstract][Full Text] [Related]
12. The expression of neuropeptides in hyperplastic and malignant prostate tissue and its possible clinical implications.
Yu DS; Hsieh DS; Chen HI; Chang SY
J Urol; 2001 Sep; 166(3):871-5. PubMed ID: 11490236
[TBL] [Abstract][Full Text] [Related]
13. Expression of neuroendocrine differentiation markers in lethal metastatic castration-resistant prostate cancer.
Sainio M; Visakorpi T; Tolonen T; Ilvesaro J; Bova GS
Pathol Res Pract; 2018 Jun; 214(6):848-856. PubMed ID: 29728311
[TBL] [Abstract][Full Text] [Related]
14. Neuroendocrine prostate cancer: subtypes, biology, and clinical outcomes.
Aggarwal R; Zhang T; Small EJ; Armstrong AJ
J Natl Compr Canc Netw; 2014 May; 12(5):719-26. PubMed ID: 24812138
[TBL] [Abstract][Full Text] [Related]
15. Association of intraductal carcinoma of the prostate detected by initial histological specimen and neuroendocrine prostate cancer: A report of three cases.
Ikeda J; Ohe C; Ohsugi H; Matsuda T; Tsuta K; Kinoshita H
Pathol Int; 2021 Sep; 71(9):621-626. PubMed ID: 34297443
[TBL] [Abstract][Full Text] [Related]
16. Platinum sensitivity in metastatic prostate cancer: does histology matter?
Humeniuk MS; Gupta RT; Healy P; McNamara M; Ramalingam S; Harrison M; George D; Zhang T; Wu Y; Armstrong AJ
Prostate Cancer Prostatic Dis; 2018 Apr; 21(1):92-99. PubMed ID: 29230006
[TBL] [Abstract][Full Text] [Related]
17. Diagnosis and management of neuroendocrine prostate cancer.
de Kouchkovsky I; Chan E; Schloss C; Poehlein C; Aggarwal R
Prostate; 2024 Apr; 84(5):426-440. PubMed ID: 38173302
[TBL] [Abstract][Full Text] [Related]
18. Prostate carcinoma with amphicrine features: further refining the spectrum of neuroendocrine differentiation in tumours of primary prostatic origin?
Prendeville S; Al-Bozom I; Compérat E; Sweet J; Evans AJ; Ben-Gashir M; Mete O; van der Kwast TH; Downes MR
Histopathology; 2017 Dec; 71(6):926-933. PubMed ID: 28756619
[TBL] [Abstract][Full Text] [Related]
19. Rational indication for docetaxel rechallenge in metastatic castration-resistant prostate cancer.
Heck MM; Thalgott M; Retz M; Wolf P; Maurer T; Nawroth R; Hatzichristodoulou G; Gschwend JE; Kübler H
BJU Int; 2012 Dec; 110(11 Pt B):E635-40. PubMed ID: 22889368
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of serum chromogranin A and prostate specific antigen in prostate cancer patients for progression to the hormone resistance state.
Zissimopoulos A; Bantis A; Sountoulides P; Giannakopoulos S; Kalaitzis C; Agelonidou E; Touloupidis S
Hell J Nucl Med; 2009; 12(3):234-7. PubMed ID: 19936334
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
